Press Releases for ISIS

Press Releases
Genzyme Reports Third-Quarter Financial Results
Alnylam and Regulus Receive Notice of Allowance from United States Patent and Trademark Office for New Patent Covering microRNA Therapeutics
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX- 011
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference
OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2009 Financial Results Conference Call
Genzyme Delivers Solid Second-Quarter Financial Results
InvestorSoup.com Issues Trading Outlook for Genta Inc.
BenchmarkJournal.Com Free Analyst Review for THQI, CTCM, JOSB, ISIS, CETV and BEAT
Antisense Therapeutics Drug ATL1101 Enhances Effect of Existing Chemotherapy Treatment on Prostate Tumors
Isis Pharmaceuticals to Present at Jefferies' 3rd Annual Healthcare Conference
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
Isis Pharmaceuticals to Present at Needham's 8th Annual Life Sciences Conference
Isis Pharmaceuticals to Present at Goldman Sachs' 30th Annual Global Healthcare Conference
Webcast Alert: Isis Pharmaceuticals To Provide General Corporate Update in Conjunction with 2009 Annual Meeting of Stockholders
Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
Webcast Alert: Isis Pharmaceuticals To Provide General Corporate Update in Conjunction with 2009 Annual Meeting of Stockholders
Regulus Therapeutics Achieves Initial Milestone in its Inflammatory Diseases Collaboration with GlaxoSmithKline
Isis Reports Strong Financial Results and Highlights for First Quarter of 2009
Isis and Collaborators Present New Research at the ATVB Annual Conference
Isis and Alnylam Form New Collaboration to Develop Single-Stranded RNAi Technology
Webcast Alert: Isis Pharmaceuticals' First Quarter 2009 Financial Results Conference Call
Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting
Zacks Analyst Blog Highlights: Isis Pharmaceuticals, Cosan Ltd., Petrobras, Bristol-Myers Squibb Co. And HSBC Holdings Plc
Isis Scientist Awarded 2009 Ebert Prize
Zacks Industry Outlook Highlights: Bristol-Myers, Johnson &Amp; Johnson and Abbott Labs
Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
Isis Acquires Common Shares and Warrants of iCo Therapeutics Inc.
Regulus Therapeutics Receives $20 Million in a Series A Equity Financing
Isis Reports Strong Financial Results and Highlights for Fiscal Year 2008
Webcast Alert: Isis Pharmaceuticals Announces Its 2008 Financial Results and Highlights Conference Call
Genzyme and Isis Begin New Clinical Trials of Mipomersen
Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
Zacks Bull & Bear of the Day Highlights: Isis Pharmaceuticals, LeapFrog, Johnson & Johnson, Exxon Mobil and iPass
Abbott and Isis Announce Hart-Scott-Rodino Clearance of Abbott's Acquisition of Ibis Biosciences, a Subsidiary of Isis
Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators Publish First Ever In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model
Zacks Analyst Blog Highlights: CDC Corp., Isis Pharmaceuticals, Inc., Genzyme Corp., Priceline.Com and American Oil & Gas, Inc.
Isis Reports Financial Results and Highlights for Third Quarter of 2008
Regulus Therapeutics and Collaborators Discover Role of a microRNA in Tumor Angiogenesis
Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review
Webcast Alert: Isis Pharmaceuticals Announces Third Quarter 2008 Financial Results Conference Call
Isis' Ibis Biosciences Subsidiary Highlights the Power of the Ibis T5000 Pathogen Identification and Characterization System at the ICAAC/IDSA Meeting
Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
Zacks Analyst Blog Highlights: Isis Pharmaceuticals, Inc., Schering- Plough Corp., Sara Lee Corp., EnCana Corp. And Euroseas Ltd.
Webcast Alert: ATL/TV1102 Phase II Results Presented at the World Congress on Treatment and Research in Multiple Sclerosis Conference Call
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Isis Receives Notices of Allowance That Significantly Expand the Scope of Key RNA Therapeutic Patents
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors
Isis Initiates Clinical Trial of CRP Drug
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance
Webcast Alert: Isis Pharmaceuticals Announces Second Quarter 2008 Financial Results Conference Call
Isis Announces Appointment of Martin P. Bedigian, M.D. as Vice President and Chief Medical Officer
Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call
Abbott Invests Additional $20M in Isis' Subsidiary Ibis Biosciences
Isis Pharmaceuticals Conference Call Notice
Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies
Genzyme and Isis Complete Licensing of Mipomersen
Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
Webcast Alert: Isis Pharmaceuticals to Provide General Corporate Update in Conjunction With 2008 Annual Meeting of Stockholders
Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology
Isis to Receive $4.6 Million From Alnylam
Isis Files S-3 Registration Statement - May 27 2008 1:01AM
Isis Reports Financial Results and Highlights for First Quarter of 2008 - Jun 1 2008 11:31PM
New Analyst Reports for GILEAD SCIENCES INC, ISIS PHARMACEUTICALS INC, CURIS INC, and MILLENNIUM PHARMACEUTICALS INC - May 27 2008 1:18AM
Webcast Alert: Isis Pharmaceuticals Announces First Quarter 2008 Financial Results Conference Call
Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases - Jun 1 2008 7:06AM
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
Regulus Therapeutics to Host Conference Call to Discuss GlaxoSmithKline Alliance
GlaxoSmithKline and Regulus Therapeutics Form Strategic Alliance To Develop MicroRNA Targeted Therapeutics to Treat Inflammatory Diseases
Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE